補体依存性細胞傷害
“Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer”. mAbs 6 (5): 1133–1144. doi:10.4161/mabs.29670. ISSN 1942-0862. PMC 4622586. PMID 25517299. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622586/.
↑ Wang, Xinhua; Mathieu, Mary; Brezski, Randall J. (2018). “IgG Fc engineering to modulate antibody effector functions”. Protein & Cell 9 (1): 63–73. doi:10.1007/s13238-017-0473-8. ISSN 1674-800X. PMC 5777978. PMID 28986820. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777978/.
1 2 3 4 Taylor, Ronald P.; Lindorfer, Margaret A. (2014). “The role of complement in mAb-based therapies of cancer”. Methods 65 (1): 18–27. doi:10.1016/j.ymeth.2013.07.027. ISSN 1095-9130. PMID 23886909.
1 2 Hernandez, Axel; Parmentier, Julie; Wang, Youzhen; Cheng, Jane; Bornstein, Gadi Gazit (2012).